Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Modalis Therapeutics Corporation ( (JP:4883) ) has issued an update.
Modalis Therapeutics Corporation has announced the issuance of 700 new shares as part of a restricted-stock-based remuneration plan for an employee of its subsidiaries. This initiative aims to enhance the company’s long-term corporate value and align the interests of its employees with those of its shareholders. The issuance is part of a broader compensation strategy approved in 2021, designed to reward contributions to the company while maintaining a minimal impact on share dilution.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, operating within the biotechnology industry. The company focuses on developing innovative therapeutics, particularly in the realm of genetic medicine, to address unmet medical needs.
Average Trading Volume: 4,181,503
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.15B
See more data about 4883 stock on TipRanks’ Stock Analysis page.